America’s Vacation Was Built on Gluttony. Ozempic Killed the Buzz.
Skift Take
For decades, the travel industry has been an economy of excess — of eating more, drinking more, spending more. But blockbuster weight-loss drugs are now reshaping consumer behavior at a population level, and with it, how travel dollars flow.
The travel industry has always been good at naming its eras – wellness, revenge travel, premium. Now another is underway, and this one comes from the pharmacy. And it’s by prescription only.
Use of blockbuster weight-loss drugs like Ozempic, Wegovy, and Mounjaro has more than doubled since early 2024. Today, more than one in eight American adults report taking these drugs specifically for weight loss. The result: the U.S. obesity rate has finally reversed course, dropping from a record 40% in 2022 to 37% in 2025.
But what makes these drugs so significant for travel isn't just their slimming effect. It's the way they seem to quiet other forms of appetite. Smaller meals. Less alcohol. A recalibration of what feels good while away from home.
The core GLP-1 demographic hits travel's sweet spot — the 40-to-64 age bracket. The industry's
